Zhang Qian, Feng Yunjiang, Kennedy Derek
School of Natural Sciences, Eskitis Institute for Drug Discovery, Griffith University, Nathan, 4111, Australia.
Cell Mol Life Sci. 2017 Mar;74(5):777-801. doi: 10.1007/s00018-016-2362-3. Epub 2016 Sep 12.
Chemotherapy is one of the most effective and broadly used approaches for cancer management and many modern regimes can eliminate the bulk of the cancer cells. However, recurrence and metastasis still remain a major obstacle leading to the failure of systemic cancer treatments. Therefore, to improve the long-term eradication of cancer, the cellular and molecular pathways that provide targets which play crucial roles in drug resistance should be identified and characterised. Multidrug resistance (MDR) and the existence of tumor-initiating cells, also referred to as cancer stem cells (CSCs), are two major contributors to the failure of chemotherapy. MDR describes cancer cells that become resistant to structurally and functionally unrelated anti-cancer agents. CSCs are a small population of cells within cancer cells with the capacity of self-renewal, tumor metastasis, and cell differentiation. CSCs are also believed to be associated with chemoresistance. Thus, MDR and CSCs are the greatest challenges for cancer chemotherapy. A significant effort has been made to identify agents that specifically target MDR cells and CSCs. Consequently, some agents derived from nature have been developed with a view that they may overcome MDR and/or target CSCs. In this review, natural products-targeting MDR cancer cells and CSCs are summarized and clustered by their targets in different signaling pathways.
化疗是癌症治疗中最有效且应用最广泛的方法之一,许多现代治疗方案能够消除大部分癌细胞。然而,复发和转移仍然是导致全身性癌症治疗失败的主要障碍。因此,为了提高癌症的长期根除效果,应当识别并表征那些提供在耐药性中起关键作用靶点的细胞和分子途径。多药耐药(MDR)以及肿瘤起始细胞(也称为癌症干细胞,CSCs)的存在是化疗失败的两个主要原因。MDR描述的是对结构和功能上无关的抗癌药物产生耐药性的癌细胞。CSCs是癌细胞中一小部分具有自我更新、肿瘤转移和细胞分化能力的细胞。CSCs也被认为与化疗耐药有关。因此,MDR和CSCs是癌症化疗面临的最大挑战。人们已经做出了巨大努力来寻找特异性靶向MDR细胞和CSCs的药物。因此,一些天然来源的药物已经被开发出来,期望它们能够克服MDR和/或靶向CSCs。在这篇综述中,靶向MDR癌细胞和CSCs的天然产物根据其在不同信号通路中的靶点进行了总结和分类。